ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.73
-0.71%
US Tech 100
21,149.60
-0.22%
S&P 500
6,071.27
-0.21%
US Dollar vs CAD
1.419
0.28%
Bitcoin
101,106.30
-0.08%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Aldeyra Therapeutics Inc (ALDX)

  7. Aldeyra Therapeutics Inc (ALDX) News

ALDX

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALDX
DateTimeSourceHeadlineSymbolCompany
12/02/20246:00AMBusiness WireAldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
11/18/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
11/18/20246:00AMBusiness WireAldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option AgreementNASDAQ:ALDXAldeyra Therapeutics Inc
11/14/20246:00AMBusiness WireAldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
11/07/20243:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
10/31/20246:00AMBusiness WireAldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingNASDAQ:ALDXAldeyra Therapeutics Inc
10/21/20247:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
10/03/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
10/03/20246:00AMBusiness WireAldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
10/02/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
09/10/20243:15PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
09/05/20246:00AMBusiness WireAldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ALDXAldeyra Therapeutics Inc
09/03/20248:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
08/14/20243:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
08/14/20243:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
08/12/20245:07PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
08/12/20244:45PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
08/08/20246:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
08/08/20246:00AMBusiness WireAldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
08/07/20243:01PMBusiness WireAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of ReproxalapNASDAQ:ALDXAldeyra Therapeutics Inc
08/01/20244:01PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALDXAldeyra Therapeutics Inc
08/01/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
08/01/20243:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALDXAldeyra Therapeutics Inc
06/20/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
06/20/20246:00AMBusiness WireAldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableNASDAQ:ALDXAldeyra Therapeutics Inc
06/13/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
06/13/20246:00AMBusiness WireAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseNASDAQ:ALDXAldeyra Therapeutics Inc
06/12/20246:00AMBusiness WireAldeyra Therapeutics to Host Investor Roundtable Q&ANASDAQ:ALDXAldeyra Therapeutics Inc
06/07/20243:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALDXAldeyra Therapeutics Inc
06/06/20243:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALDXAldeyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALDX

Your Recent History

USOTC
KGKG
Kona Gold Beverage (PK)
USOTC
AXXA
Exxe (PK)
NASDAQ
FCEL
FuelCell Energy
USOTC
PSRU
Valiant Eagle (PK)
USOTC
XERI
Xeriant (QB)
NASDAQ
TSLA
Tesla
NASDAQ
LWLG
Lightwave Logic
USOTC
RDGL
Vivos (QB)
USOTC
ENZC
Enzolytics (PK)
USOTC
CEOS
CeCors (PK)
USOTC
TPTW
TPT Global Tech (CE)
USOTC
ERHE
ERHC Energy (CE)
USOTC
AABB
Asia Broadband (PK)
NASDAQ
NXPL
NextPlat
USOTC
ZHUD
Zhuding (PK)
USOTC
BMXI
Brookmount Explorations (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved